2. We are building a comprehensive,
clinically validated map of the
immune system with single-cell
biology and AI, unlocking critical
knowledge about the biological
mechanisms that drive human
immune response.
On the basis of this map, we unfold
new therapeutic discoveries,
accelerate drug development and
improve patient diagnosis and
outcomes.
Our mission is to decode and reprogram the
immune system to improve the lives of millions
of people worldwide through innovative health
research.
3. Our team spans New York City, Tel Aviv, San Francisco,
Zurich and Prague
Founded in December 2018, immunai
is a rapidly growing team of close to
130 individuals, working together on a
common mission.
We value diversity and are proud of
the different professions, backgrounds,
expertise and beliefs that make up
Immunai’s unique ways of thinking.
Our People
Our People
4. We are a multidisciplinary team of immunologists,
genomics, technologists, computer scientists,
engineers, mathematicians and operators, singularly
focused on solving an audacious challenge.
Backed by some of the leading scientific minds in
immunology, oncology, and single cell genomics, we
have a more granular understanding of the immune
system.
Our Team
Our Team
Our people are united by two shared qualities:
being exceptional at what they do and caring deeply
about making positive changes in the world.
5. Artificial Inteligence
Artificial Inteligence
AI has revolutionized genomic and clinical research. Deep learning is increasingly
being applied to answer big, previously unattainable research questions in
genomics. This includes research that sheds light on epigenetic function,
predicting regions in the genome, and predicting protein binding (1), as well as the
study of clinical significance of genetic variants in order to improve diagnostics
and therapeutics (2). The scale, heterogeneity and high dimensionality of the data
generated from single-cell sequencing, combined with the inherent immense
complexity of the immune system, presents a uniquely relevant space for AI and
ML applications to generate novel and important insights (3).
Our team is embracing the opportunity and leveraging AI for a variety of
challenges ranging from identifying subtle changes in cell types and states, to
finding predictive biomarkers of response or resistance to specific therapeutic
regimens.
6. Computational Biology
Computational Biology
Advances in single-cell genomics technologies allow us to study the immune system at an unprecedented degree of
granularity, and enable us to embrace the full heterogeneity and complexity of the system. We can now generate an
immense amount of data for every cell, including its gene expression patterns, its surface proteome, and its unique
antigen-binding receptor sequence (4). By generating data at this degree of resolution, we discover novel insights into
the immune drivers of health and disease, study the mechanisms of action and resistance of emerging therapeutics, and
identify patient subsegments that are most likely to respond to a specific treatment (5).
At Immunai, we are focused on developing state-of-the-art computational methods to fully leverage the potential of single-
cell data (6,7). We have devised a robust computational pipeline for data integration and cell annotation. This enables us
to eаiciently analyze longitudinal multi-omic data and characterize the immune response under various conditions and
treatments. Our computational methods, combined with our extensive in-house single-cell dataset, provide us with a high
resolution understanding of the immune response even in rare cell types, which we apply towards development of new
drugs and improving current therapeutics across multiple diseases.
And with the constant advances of single-cell technologies, many more exciting challenges await!
7. Genomics & Immunology
Genomics & Immunology
While it has been long recognized that the behaviors of individual cells
are the crucial drivers of health and disease, it is only in the last few
years where technological advances have allowed transcriptome-
wide analysis of individual cells in high-throughput. This single-cell
resolution is especially important for the study of the adaptive immune
system, with its near infinite combinations of TCR and BCR repertoires
layered on top of its diversity of phenotypic states (8).
By linking each cell’s clonality data with its transcriptomic and
phenotypic state (9), we are unlocking new ways to study everything
from progression of disease to resistance to therapeutics, to the
development of more eаicacious, less toxic gene- and cellular
therapies (10). As we (11) and others (12) continue to develop new single
cell assays that allow us to extract even more data and deeper layers
of molecular insights from every cell, we will continue to increase the
resolution of our understanding of the immune system in health and
disease.
8. Software Development
Software Development
In software, our job is to enable Immunai’s scientists to ask questions
on novel datasets at an unprecedented scale. Over two short years,
we’ve done this and are constantly innovating on the world’s largest
single cell sequencing data platform. We process and organize
hundreds of terabytes of single-cell sequencing data - a scale that
is an industry first. Our pipeline, which is a collaboration between
software engineers, computational biologists, and immunologists,
extracts insights from high-dimensional datasets (13) with autonomy,
reproducibility, and flexibility. The result is a set of tools that removes
the burden of technical problems such as data scale and provenance
and that empowers our science.
9. Operations
Operations
Operations at Immunai support five global sites to achieve
operating targets, improve eаiciencies, and enable the
company to scale the business as we implement our strategic
vision. The team is accountable for Logistics, HR Operations,
Procurement, Vendor Management, Process Improvement,
Facilities, IT Support, Travel, and the Biorepository. Our team
works diligently to provide our scientific teams with the
infrastructure they need to realize their vision.